search
Back to results

Safety and Efficacy of Implantation of Two Multifocal Intraocular Lenses in the Treatment of Senile Cataract

Primary Purpose

Senile Cataract

Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Acri.LISA366D multifocal aspheric IOLs
TecnisZ9001 multifocal aspheric IOLs
Sponsored by
Qinghai University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Senile Cataract

Eligibility Criteria

50 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Clinically diagnosed as age-related cataract.
  • Corneal astigmatism < 1.0 D
  • Lens hardness, II-III
  • Initial surgery on the eye
  • Age 50-80 years
  • Healthy and able to tolerate anesthesia and surgery

Exclusion Criteria:

  • Glaucoma or secondary vision loss resulting from diabetes, hypertension, intracranial tumors and neurological diseases
  • Fundus disease, corneal edema, corneal opacity, endophthalmitis, and/or iris adhesion.
  • Prior experience of eye surgery
  • Failure to make regular referrals
  • Autoimmune disease, mental illness or other serious systemic disease
  • Inability to cooperate with the researchers
  • Inability to tolerate surgery
  • Sensitivity, anxiety or the pursuit of perfection
  • Inability to give informed consent

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Experimental

    Arm Label

    the test group

    the control group

    Arm Description

    The patients aged 50-80 years will be randomly assigned to implantation of Acri.LISA366D multifocal aspheric IOLs in the test group.

    The patients aged 50-80 years will be randomly assigned to implantation of TecnisZ9001 multifocal aspheric IOLs in the control group.

    Outcomes

    Primary Outcome Measures

    Number of cataract participants with good biocompatibility of intraocular lens implants
    Good engraftment, epithelialization, no neovascularization, retained transparency, no host inflammatory reaction.

    Secondary Outcome Measures

    Visual acuity
    Best spectacle corrected visual acuity

    Full Information

    First Posted
    November 9, 2016
    Last Updated
    November 14, 2016
    Sponsor
    Qinghai University
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02966496
    Brief Title
    Safety and Efficacy of Implantation of Two Multifocal Intraocular Lenses in the Treatment of Senile Cataract
    Official Title
    Safety and Efficacy of Implantation of Two Multifocal Intraocular Lenses in the Treatment of Senile Cataract: a Randomized Controlled Clinical Trial
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    November 2016
    Overall Recruitment Status
    Unknown status
    Study Start Date
    January 2016 (undefined)
    Primary Completion Date
    June 2017 (Anticipated)
    Study Completion Date
    December 2018 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Qinghai University

    4. Oversight

    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    This trial is designed to compare the biocompatibility and long-term visual outcomes of the Tecnis Z9001 and Acri.LISA 366D multifocal IOLs used for the treatment of senile cataract. The aim is to provide a safer biomaterial for senile cataract treatment, achieving better postoperative visual quality and fewer complications.
    Detailed Description
    History and current studies Aging-induced degenerative diseases are the leading cause of senile cataract. Phacoemulsification with intraocular lens (IOL) implantation is a commonly employed surgical technique for the treatment of cataract. A traditional IOL is spherical and monofocal. Traditional monofocal IOL implantation allows cataract patients to obtain good postoperative distance vision but loss of accommodation results in poor near vision. Following monofocal IOL implantation, most patients still require the use of glasses. Fortunately, the presence of multifocal IOLs solves this problem. Studies have shown that aspheric IOLs with zero or negative spherical aberration can eliminate or reduce the spherical aberration of the whole eye and can improve contrast sensitivity and night vision compared with a spherical IOL. As first reported in 1987 by Keatea et al., multifocal IOLs were introduced to provide improved visual acuity, thus eliminating the need to wear glasses and improving the patient's quality of life. Increasing evidence-based medicine evidences have shown that multifocal IOLs are more adept to improving near vision than single-focus IOLs. To date, various types of multifocal IOLs have been developed and according to different design principles, clinically used multifocal IOLs have been divided into refraction type, diffraction type and refraction/diffraction type. Introduced in 2002, the Tecnis Z9001 diffractive multifocal aspherical IOL (Abbott Medical Optics, CA, USA) is clinically proven to give patients improved contrast vision and visual quality when compared with the common IOL, although deficiencies include postoperative glare and reduced contrast sensitivity. Emerging designs for multifocal IOLs aim to provide improvements in postoperative visual quality. The Acri.LISA 366D multifocal aspheric IOL is a relatively novel refractive/diffractive multifocal IOL that is different from traditional IOLs. Its unique optical design improves the patient's full vision and reduces the incidence of light scattering, glare and halo, which is expected to deliver better clinical outcomes. However, its long-term clinical performance and the potential incidence of complications still need further evaluation. It is worth noting that as age increases, the increase in presbyopia, aberrations and lens scattering reduces the compensation for corneal aberrations, thereby resulting in a decrease in visual acuity and contrast sensitivity. Given this, ideal IOLs should have good biocompatibility and good resolution with no spherical aberration. Data collection, management, analysis, and open access Data collection Clinical data will be collected and managed using an electronic data capture system. All data relevant to the trial will be recorded in electronic case report forms that will be provided by the sponsor personnel. The case report will be completed after the interview. Data management After completion of follow-up and data confirmation, only the project manager will lock the database. The locked data will be unable to be altered and will be preserved for future reference by the Affiliated Hospital of Qinghai University in China. Data analysis All data will be statistically analyzed by professional statisticians. Open data Published data will be released at http://www.medresman.org. Statistical analysis All data will be statistically analyzed by statisticians using SPSS v19.0 software. Normally distributed measurement data will be expressed as mean ± standard deviation, while non-normally distributed data will be expressed as quartiles and medians. Categorical variables will be expressed as counts and percentages. Two-sample t-test or Mann-Whitney U-test will be used for intergroup comparison of visual acuity and diopter. The chi-squared test or Fisher's exact test will be used for intergroup comparison of incidence of histocompatibility reactions between the implant and host tissues and the percentage of complications. A value of P < O.05 will be considered statistically significant.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Senile Cataract

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantInvestigator
    Allocation
    Randomized
    Enrollment
    40 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    the test group
    Arm Type
    Experimental
    Arm Description
    The patients aged 50-80 years will be randomly assigned to implantation of Acri.LISA366D multifocal aspheric IOLs in the test group.
    Arm Title
    the control group
    Arm Type
    Experimental
    Arm Description
    The patients aged 50-80 years will be randomly assigned to implantation of TecnisZ9001 multifocal aspheric IOLs in the control group.
    Intervention Type
    Biological
    Intervention Name(s)
    Acri.LISA366D multifocal aspheric IOLs
    Intervention Description
    The implantation of Acri.LISA366D multifocal aspheric IOLs are used in the test group.
    Intervention Type
    Biological
    Intervention Name(s)
    TecnisZ9001 multifocal aspheric IOLs
    Intervention Description
    The implantation of TecnisZ9001 multifocal aspheric IOLs are used in the test group.
    Primary Outcome Measure Information:
    Title
    Number of cataract participants with good biocompatibility of intraocular lens implants
    Description
    Good engraftment, epithelialization, no neovascularization, retained transparency, no host inflammatory reaction.
    Time Frame
    month 12 after surgery
    Secondary Outcome Measure Information:
    Title
    Visual acuity
    Description
    Best spectacle corrected visual acuity
    Time Frame
    at month 1, month 3, month 6, month 12 and month 24 after surgery

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    50 Years
    Maximum Age & Unit of Time
    80 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Clinically diagnosed as age-related cataract. Corneal astigmatism < 1.0 D Lens hardness, II-III Initial surgery on the eye Age 50-80 years Healthy and able to tolerate anesthesia and surgery Exclusion Criteria: Glaucoma or secondary vision loss resulting from diabetes, hypertension, intracranial tumors and neurological diseases Fundus disease, corneal edema, corneal opacity, endophthalmitis, and/or iris adhesion. Prior experience of eye surgery Failure to make regular referrals Autoimmune disease, mental illness or other serious systemic disease Inability to cooperate with the researchers Inability to tolerate surgery Sensitivity, anxiety or the pursuit of perfection Inability to give informed consent
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Ping Yu, Master
    Organizational Affiliation
    Affiliated Hospital of Qinghai University
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    Undecided

    Learn more about this trial

    Safety and Efficacy of Implantation of Two Multifocal Intraocular Lenses in the Treatment of Senile Cataract

    We'll reach out to this number within 24 hrs